Skip to main content Skip to main navigation Skip to footer Skip to search

614-864-4919 info@sermonixpharma.com

LinkedIn
Facebook
Twitter
RSS

LinkedIn
Facebook
Twitter
RSS

About
Breast Cancer
Pipeline
- Lasofoxifene
ELAINE Studies
News & Media
- News
- Media
Posters & Presentations
Contact

Select Page

side_arrow

by Sermonix Pharmaceuticals | Jan 6, 2020 | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Search for:

Recent Posts

Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, Demonstrates Promising Ki67 Suppression in Phase 2 I-SPY 2 Arm Evaluating Therapy in Neoadjuvant Breast Cancer Setting
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast Cancer
Sermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting

Recent Comments

Archives

Categories

News

Meta

Log in
Entries feed
Comments feed
WordPress.org

© Sermonix Pharmaceuticals